Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer

Table 1 Treatment effects on mouse energy balance and growth of MCF-7 and MDA-MB231 breast cancer xenografts

	MCF-7 (estrogen-receptor-positive) xenografts		MDA-MB231 (estrogen-receptor-negative) xenografts
	PEG-LPrA2	Sc-PEG	PEG-LPrA2	Sc-PEG
Initial food intake (g/day)	2.2 ± 0.7	2.2 ± 0.4	2.6 ± 0.6	2.4 ± 0.2
Final food intake (g/day)	2.9 ± 0.5	2.8 ± 0.4	2.9 ± 0.6	2.9 ± 0.4
Food intake change (g/day)	+0.7	+0.6	+0.3	+0.5
Initial body weight (g)	19.7 ± 2.0	19.6 ± 0.7	18.8 ± 0.7	19.2 ± 0.3
Final body weight (g)	23.9 ± 0.7	24.9 ± 1.3	19.3 ± 1.3	20.0 ± 1.4
Body weight change (g)	+4.2	+5.3	+0.5	+0.8
Carcass weight (g)	17.1 ± 1.0	17.9 ± 0.7	14.2 ± 1.2*	14.6 ± 0.2*
Final tumor volume (mm³)	20.5 ± 5.0	>1,100 ± 180	210 ± 29	430 ± 45
n	10	10	10	10

Data expressed as mean ± standard deviation (n = 10 tumors/breast cancer type/treatment). *P < 0.05, significant difference in carcass weight of mice hosting MDA-MB-231 breast cancer xenografts treated with pegylated leptin peptide receptor antagonist 2 (PEG-LPrA2) or pegylated scrambled peptide (Sc-PEG) with respect to mice hosting MCF-7 breast cancer xenografts (n = 10 tumors/treatment).

ISSN: 1465-542X